Granzyme B mediates both direct and indirect cleavage of extracellular matrix in skin after chronic
莫博赛替尼化学结构

莫博赛替尼化学结构全文共四篇示例,供读者参考第一篇示例:莫博赛替尼(Imatinib,商品名格列卫)是一种靶向治疗白血病的药物,也被用于治疗一些其他类型的癌症。
它是通过靶向特定的蛋白质,从而阻断癌细胞的生长和扩散。
莫博赛替尼的化学结构是一种非常复杂的有机分子,其分子式为C29H31N7O,分子量为493.604克/摩尔。
莫博赛替尼的化学结构包含一个核心环结构,由苯环和嘧啶环连接而成。
苯环是由六个碳原子和六个氢原子组成的环状结构,而嘧啶环是由一个氮原子和四个碳原子组成的环状结构。
这两个环通过一个氮原子相连,形成了一种特殊的结构,这种结构对于莫博赛替尼的药效非常重要。
莫博赛替尼在体内主要靶向作用于一种叫做BCR-ABL融合蛋白的蛋白质。
这种融合蛋白质是一种异常的蛋白质,由Bcr(一种信号传导蛋白)和Abl(一种酪氨酸激酶)两种蛋白质的部分结构融合而成。
这种异常蛋白质的产生是由于某些白血病细胞的染色体发生了特定的基因突变,导致Bcr和Abl两种基因相互融合。
而莫博赛替尼正是针对这种异常的蛋白质进行靶向治疗的。
莫博赛替尼的化学结构设计和药效机制是经过长期的研究和开发的。
科学家们通过不断的实验和研究,逐渐了解了白血病细胞的基因突变以及融合蛋白质的结构和功能特点。
通过对这些信息的深入研究,他们最终设计出了莫博赛替尼这种能够精准干预癌细胞生长的药物。
莫博赛替尼在临床应用中被证实具有显著的疗效,尤其是对于慢性髓细胞白血病(CML)和胃肠间质瘤(GIST)等罕见白血病和恶性肿瘤的治疗效果非常显著。
通过连续服用莫博赛替尼,患者的白血细胞数量可以得到控制,进而延缓疾病的进展并提高生存率。
莫博赛替尼的治疗效果和安全性已经得到了许多临床试验和长期随访的验证,被广泛应用于临床治疗。
莫博赛替尼是一种非常重要的抗癌药物,通过靶向作用于异常蛋白质来抑制癌细胞的生长和扩散。
其化学结构复杂且精确,对于白血病和其他类型的癌症具有显著的治疗效果。
司美格鲁肽联合达格列净、二甲双胍在肥胖型2_型糖尿病合并非酒精性脂肪肝患者中的疗效分析

DOI:10.16658/ki.1672-4062.2024.01.019司美格鲁肽联合达格列净、二甲双胍在肥胖型2型糖尿病合并非酒精性脂肪肝患者中的疗效分析叶娟,陈冬,邱振汉,吴盛钊安徽省淮南市寿县人民医院内分泌科,安徽寿县232200[摘要]目的研究司美格鲁肽联合达格列净、二甲双胍在肥胖型2型糖尿病(Type 2 Diabetes Mellitus, T2DM)合并非酒精性脂肪肝(Non-alcoholic Fatty Liver, NAFLD)患者中的疗效。
方法选取2021年6月—2023年6月安徽省淮南市寿县人民医院内分泌科收治的80例肥胖型T2DM合并NAFLD患者为研究对象。
根据随机数表法分为对照组和观察组,各40例。
对照组给予二甲双胍联合达格列净治疗,观察组在对照组基础上联合司美格鲁肽治疗。
比较两组治疗12周后的疗效以及药物不良反应发生率。
结果观察组胰岛素抵抗指数、血糖指标、血脂指标、肝功能指标均显著低于对照组,差异有统计学意义(P均<0.05);观察组体质指数为(28.19±0.92)kg/m2,低于对照组的(30.12±1.47)kg/m2,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。
结论肥胖型T2DM合并NAFLD患者治疗中,相对于单纯使用达格列净、二甲双胍治疗,联合司美格鲁肽在降低血糖、血脂、肝酶,改善胰岛功能方面效果更优,且不良反应无明显增加。
[关键词] 司美格鲁肽;达格列净;二甲双胍;肥胖;2型糖尿病;非酒精性脂肪肝[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062(2024)01(a)-0019-04Efficacy of Smaglutide Combined with Dapagliflozin and Metformin in Pa⁃tients with Obese Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver DiseaseYE Juan, CHEN Dong, QIU Zhenhan, WU ShengzhaoDepartment of Endocrinology, Huainan Shouxian People's Hospital, Shouxian, Anhui Province, 232200 China[Abstract] Objective To study the efficacy of semiglutide combined with dapagliflozin and metformin in patients with obese type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD). Methods A total of 80 obese patients with T2DM combined with NAFLD were selected from the department of endocrinology of Shouxian People's Hospital from June 2021 to June 2023. They were divided into control group and observation group according to ran⁃dom number table method, 40 cases each. The control group received metformin with dagagliflozin, and the observa⁃tion group was treated with semegallutide on the basis of the control group. Comparing the efficacy and the incidence of adverse drug reactions after 12 weeks of treatment. Results The homa-ir insulin resistance index, blood glucose in⁃dex, blood lipid index and liver function index were significantly lower than that of the control group, and the differ⁃ences were statistically significant (all P<0.05). The body mass index in the observation group was (28.19±0.92) kg/m2, which was lower than (30.12±1.47) kg/m2in the control group , and the difference was statistically significant (P< 0.05). The incidence of adverse reactions was not significant (P>0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion In the treatment of obese T2DM [作者简介]叶娟(1990-),女,硕士,主治医师,研究方向为内分泌科与代谢病。
三丁基锡(TBT)化合物与牛血清白蛋白(BSA)的相互作用

度 比为 3: ,醇水 比 1 ,HAcNa c缓 冲溶液 浓度 4 . 1 O - A 00 mmo ・ 一 , H . , lL p 45O . ) . , 同浓度缓 冲溶液为参 比。 长范围 2 0 5 r,1 0c 波 1  ̄3 0nn . m石
一
1 2 1 紫外光谱 .. B A溶液 浓度 1O × 1 to ・L 。 s . 0 0 o l _ ,TB T与 B A 浓 S
[] 2
,
也是 目前 已确 认 的 内分 泌干 扰物 质[ 。海 洋 生 物 对 3 ]
T T有很强 的富集能力 , T T通过食物链可进入人体 。 B 使 B ] 血清 白蛋 白是血浆中最为丰富的蛋 白质 ,具有运 载和贮存 功 能, 含有多种可配位基团 ,能与许 多内源及外 源性化 合物结 合。 B T T进入人体 内如与血清 白蛋 白作用 , 则可 能影响甚至 改变其固有结构和功能 ,因此 研究 T T 与血清 白蛋 白的相 B 互作用有着重要意义[ 。近年来 , 们对血 清 白蛋 白与 内源 5 ] 人 性化合 物 、 药物分子及金属离子等的相 互作用 已进行 了较为
×1 to ・ 储备液 , 0 ol L 保存于 O ~4℃冰箱中) 其他试剂 ;
均为优级纯或分析纯。 实验用水 为超纯水。
1 2 实 验 方 法 . 。
海洋造成对许多非 目标生物产生毒害作用 。因此 , B T T被认 为是迄今为止人 为引入 海洋 环境 中毒性 最 大 的有 毒 物质 之
摘 要 通过紫外 、 荧光和圆二色 (D 光谱 , C) 研究 了船体 防污漆 的防污成分三丁基锡 ( B ) T T 化合物 与牛血 清 白蛋 白( S 的相互作用 ,考察 了浓度 、 B A) 酸度和有机 溶剂 等因素 的影响。结 果表 明,T T与 B A 的相互 B S
GENMED线粒体功能詹纳斯绿B染色试剂盒产品说明书范文(中文版)

GENMED线粒体功能詹纳斯绿B染色试剂盒产品说明书范文(中文版)GMS10015v.A主要用途GENMED线粒体功能詹纳斯绿B染色试剂是一种旨在通过一种毒性较小的碱性染料特异性地使具有活性功能的线粒体呈现蓝绿色,从而判断线粒体功能的完整性的权威而经典的技术方法。
该技术由大师级科学家精心研制、成功实验证明的。
其适用于各种线粒体(动物、人体、植物、昆虫等)制备物的功能检测。
产品严格无菌,即到即用,活体检测,操作简捷,性能稳定。
技术背景线粒体是细胞中重要的细胞器,其主要功能是提供细胞内各种物质代谢所需要的能量。
线粒体大量存在于代谢旺盛的细胞中,如动物的心肌、肝、肾等器官和组织的细胞中。
大量制备线粒体就是从这些器官组织中提取,或从组织培养细胞中提取。
在光学显微镜下线粒体呈现为颗粒状、棒状或弯曲细线。
詹纳斯绿B(JanugreenB),是一种毒性较小的碱性染料。
它可以对活细胞进行直接染色,在细胞质内可以看到被染成蓝绿色的线状或颗粒小体的线粒体。
线粒体所以能显示出蓝绿色,是由于线粒体中具有细胞色素氧化酶系统,它是染料始终处于氧化状态呈蓝绿色,而在周围的细胞质中的染料被还原呈无色。
产品内容毫升毫升毫升份保存方式保存在-20℃冰箱里;GENMED染色液(ReagentB),避免光照;有效保证6月用户自备毫升离心管:用于线粒体染色的容器光学显微镜:用于线粒体染色观察分析实验步骤实验开始前,将℃冰箱里的试剂盒中的GENMED染色液(ReagentB)置于冰槽里融化,并放在暗室里。
然后进行下列操作。
一、纯化线粒体染色1.从纯化的线粒体样品中移出至微升(含细胞中提取的线粒体)到新的预冷的毫升离心管,置于冰槽里(注意:线粒体须均匀分布,没有聚集成团)2.加入等量微升的GENMED染色液(ReagentB),轻柔混匀3.放进暗室里,在室温下孵育1分钟4.即刻移取微升到载玻片上,放上盖玻片5.在光学显微镜油镜下进行观察:功能完整的线粒体呈现蓝绿色圆形或椭圆形颗粒(注意:可见蓝绿色渐渐变淡现象)6.篮绿色强度显著减弱或呈现无色,表明线粒体细胞色素氧化酶系统功能不全或功能丧失二、活体细胞染色1.将待测细胞(某细胞)移入到1.5毫升离心管2.放进微型台式离心机离心1分钟,速度为500g(或2000RPM;例如eppendorf5415)3.小心抽去上清液4.加入微升GENMED清理液(ReagentC)或GENMED保存液(ReagentA)5.加入微升GENMED染色液(ReagentB),充分混匀6.放进暗室里,在冰槽里孵育分钟7.即刻移取微升到载玻片上,放上盖玻片8.在光学显微镜油镜下进行观察:功能完整的线粒体呈现蓝绿色线状或颗粒小体9.篮绿色强度显著减弱或呈现无色,表明线粒体细胞色素氧化酶系统功能不全或功能丧失注意事项1.本产品为20次(活体细胞)或400次(纯化线粒体)操作2.所有操作均须无菌状态下进行3.线粒体样品操作须在低温下进行,且操作快速4.操作时,须戴手套5.建议染色完成后,即刻进行显微镜观察分析6.孵育时,须避免光照7.本公司提供系列线粒体试剂产品质量标准1.本产品经鉴定性能长期稳定2.本产品经鉴定显色清晰使用承诺友情提醒IFITDOESN’TWORK,RECHECKYOURE某PERIMENTTOSEEWHATYOUDIDWRONG。
基因启动子PPT课件

• 水稻的actin1基因启动子仅不在木质部中起作用。
.
15
拟南芥ACTIN2基因启动子分析
.
16
.
17
原核生物组成型启动子之二: 农杆菌胭脂碱合成酶基因启动子 Nos promoter
卫矛 烟草
Nos promoter Nos promoter 35S promoter
.
18
2.诱导型启动子(Inducible Promoters
• Promoter: located in the structural gene 5 'upstream, can guide the RNA polymerase with template correctly,start a DNA sequence of the gene transcription
CAAT框(CAAT box)
TATA框(TATA组成型启动子微生物来源的
• (constitutive promoter)
植物来源的
• 2.诱导型启动子 Stress/wound -inducible promoters • (inducible promoter)
现代遗传学精要
基因启动子
gene promoters
免疫学名词解释

1、Lymphocyte homing(淋巴细胞归巢):The process by which particular subsets of lymphocytes selectively enter and residue in peripheral lymphoid organs. It’s mediated by homing receptor on T lymphocytes and addressin on endothelial cells.2、Lymphocyte recirculation(淋巴细胞再循环):is the process by which lymphocytes continuously move between sites throughout the body through blood and lymphatic vessels, and it’s critical for the initiation and effectors phase of immune response.3、Hapten(半抗原):Substances which can combine with TCR, BCR or Ab, but cannot induce immune response independently.4、Sequential/Linear determinants(顺序型/线性决定簇):are epitopes formed by several adjacent amino acid residues. They exist on the surface or inside of antigen molecules. They are mainly recognized by T cells, but some also can be recognized by B cells.5、Conformational determinants(构象型决定簇):are epitopes formed by amino acid residues that aren’t ina sequence but become spatially juxtaposed in the folded protein. They normally exist on the surface of antigen molecules and can be recognized by B cells or Ab.6、T cell epitope(T细胞表位):Antigen epitopes recognized by T cells(TCR).Features: peptides; sequential determinants; exist in anywhere of Ag; after processed, presented by MHC molecules; 8~23 amino acid residues long.7、TI-Ag/Thymus independent Ag(胸腺依赖性抗原): Ag which can stimulate B cells to produce Ab without the help of T cells and macrophages.8、TD-Ag/Thymus independent Ag(非胸腺依赖性抗原): Ag which can stimulate B cells to produce Ab with the help of T cells.9、Heterophile Ag/Forssman Ag(异嗜抗原): Common Ags shared by different species. They have no specificity of species and play an important role in immunopathology and diagnosis.10、CDR/Complementary determining region(互补决定区): The six HVR of H chain and L chain are brought together to form antigen-binding surface, so HVR is also called CDR.11、Idiotype/Idiotype determinant(独特型/独特型表位): The unique structure located in the V region of Ig ,BCR or TCR which show different immunogenicity due to the different amino acid sequence of HVR or CDR. It’s a unique Ag-specific marker for each Ig in an individual.12、Opsonization(调理作用):refers to the functions of IgG and IgM that after their Fab fragments bind Ag, their Fc fragments bind macrophage to enhance the phagocytosis of macrophage;or the functions of C3b and C4b on the microbe surface that bind to CR1 on the macrophage surface to enhance the phagocytosis of macrophage.13、ADCC/Antibody dependent cell mediated cytoxicity(抗体依赖的细胞介导的毒性作用):It’s a process in which FcR of NK cells, macrophages and monocytes bind to Fc fragment of Ab(IgG,IgA,IgE) coated target cells resulting in lyses of target cells.14、mAb /McAb/Monoclonal Ab (单克隆抗体):Ab produced by single B cell clone or one hybridomas clone and having a single specificity.(Immunized spleen cells(B) hybride with myeloma cells----hybridomas) 15、MAC/Membrane attack complex(攻膜复合体):C5b6789 complex which leads to formation of a hole in the membrane and mediates lysis of target cell.16、CKs/Cytokines(细胞因子):are small polypeptides produced in response to microbes and other Ags secreted by activated immunocytes or some matrix cells that mediate and regulate immune and inflammatory reactions by binding corresponding receptor on cells.17、IFN(干扰素):The CKs produced by human or animal tissue cells or T lymphocytes and NK cells,following the infection of virus and exposure to antigen whose principle function is to inhibit virusreplication or activate macrophage in both innate immunity and adaptive immunity.18、CAMs /Ams/cell adhesion molecules (黏附分子):The cell surface proteins involved in the interaction of cell-cell or cell-extracellular matrix. They play a crucial role in cell interaction, recognition, activation and migration by binding of receptor and ligand.19、CD/cluster of differentiation (分化簇):It is a group of cell surface molecules associated with the development and differentiation of immune cells.20、MHC/major histocompatibility complex(主要组织相容性复合体):A large cluster of linked genes located in some chromosomes of humanity or other mammals that encode major histocompatibility antigen and relate to allograft rejection, immune response and cell-cell recognition.21、HLA/Human leukocyte antigen(人类白细胞抗原):The major histocompatibility antigens for humanity which are associated with histocompatibility and immune response. They are alloantigens which are specific for each individual.22、HLA complex(HLA复合体):The MHC of humanity, a cluster of genes which encode for HLA and related to histocompatibility and immune response.23、MHC restriction(MHC 限制性):In interaction of T cell and APC or target cells, T cells not only recognize specific antigen but also recognize polymorphic residues of MHC molecules.24、PAMP/pathogen associated molecular pattern( 病原相关分子模式): The distinct structures or components that are common for many pathogens ,such as LPS, dsRNA of viruses etc.25、PRR/ pattern recognition receptor (模式识别受体): The receptors on macrophage that can recognize and bind PAMP on some pathogen, injured or apoptotic cells, including mannose receptor, scavenger receptor , toll like receptor etc.26、APC/Antigen presenting cells/Accessory cells/A cells(抗原递呈细胞): A group of cells which can uptake and process antigen and present antigen-MHC-Ⅰ/Ⅱcomplex to T cells, playing an important role in immune response.27、Cross-priming/Cross-presentation (交叉递呈): A mechanism by which a professional APC activates, a naïve CD8 CTL specific for the antigens of a third cell (e.g. a virus-infected or tumor cell)28、ITAM /immunoreceptor tyrosine-based activation motif(免疫受体酪氨酸活化基序): ITAM transduces activation signals from TCR, composing of tyrosine residues separated by around 18 aas. When TCR specially bind to antigen, the tyrosine becomes phosphorylated by the receptor associated tyrosine kinases to transduct active signals.29、TCR complex(TCR复合物): A group of membrane molecules on T cells that can specifically bind to antigen and pass an activation signal into the cell, consisting of TCR(αβ,γδ),CD3 (γε,δε)andδ-δ。
蛋白酶抑制剂混合物(细菌抽提用, 100X)

北京索莱宝科技有限公司
蛋白酶抑制剂混合物(细菌抽提用,100X)
货号:P6734
规格:100T
保存:-20ºC避光保存,有效期12个月。
4ºC保存,2个月有效;室温保存,2周有效。
产品组成:
产品名称规格保存蛋白酶抑制剂混合物(细菌抽提用,100X)1mL-20ºC避光
0.1M EDTA,pH8.01mL RT
产品说明:
细菌提取物中含有许多内源性的蛋白酶、磷酸酶等,容易导致提取物中的蛋白降解或去修饰,从而影响后续的蛋白检测。
因此在提取物中添加适当的蛋白酶、磷酸酶等抑制剂是防止蛋白降解和去修饰的有效方法。
本产品为经优化和测试的用于细菌蛋白提取的蛋白酶抑制剂混合物,包含了广谱的丝氨酸、半胱氨酸和酸性蛋白酶抑制剂、以及氨基肽酶抑制剂。
以1:100的比例分别把蛋白酶抑制剂混合物(细菌抽提用,100X)和0.1M EDTA加入裂解液中,即可用于细菌蛋白的提取,并有效抑制蛋白降解。
适用范围:
抑制细菌提取物中的各种蛋白酶活性,如丝氨酸蛋白酶、氨基肽酶、半胱氨酸蛋白酶、苏氨酸和天冬氨酸蛋白酶、金属蛋白酶等。
使用方法:
1、蛋白酶抑制剂混合物(细菌抽提用,100X),使用时分别按照1:100的比例加入到裂解液中,混匀后即可使用。
含有蛋白酶磷酸酶抑制剂混合物的裂解液宜现用现配,不宜配制后冻存待后续使用。
2、根据需要,0.1M的EDTA也按照1:100的比例加入到裂解液中。
第1页共1页。
稳定性英文版

HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationFLUOXETINE HClC17H18F3NO•HClM.W. = 345.79CAS — 59333-67-4STABILITY INDICATINGA S S A Y V A L I D A T I O NMethod is suitable for:ýIn-process controlþProduct ReleaseþStability indicating analysis (Suitability - US/EU Product) CAUTIONFLUOXETINE HYDROCHLORIDE IS A HAZARDOUS CHEMICAL AND SHOULD BE HANDLED ONLY UNDER CONDITIONS SUITABLE FOR HAZARDOUS WORK.IT IS HIGHLY PRESSURE SENSITIVE AND ADEQUATE PRECAUTIONS SHOULD BE TAKEN TO AVOID ANY MECHANICAL FORCE (SUCH AS GRINDING, CRUSHING, ETC.) ON THE POWDER.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationTABLE OF CONTENTS INTRODUCTION........................................................................................................................ PRECISION............................................................................................................................... System Repeatability ................................................................................................................ Method Repeatability................................................................................................................. Intermediate Precision .............................................................................................................. LINEARITY................................................................................................................................ RANGE...................................................................................................................................... ACCURACY............................................................................................................................... Accuracy of Standard Injections................................................................................................ Accuracy of the Drug Product.................................................................................................... VALIDATION OF FLUOXETINE HCl AT LOW CONCENTRATION........................................... Linearity at Low Concentrations................................................................................................. Accuracy of Fluoxetine HCl at Low Concentration..................................................................... System Repeatability................................................................................................................. Quantitation Limit....................................................................................................................... Detection Limit........................................................................................................................... VALIDATION FOR META-FLUOXETINE HCl (POSSIBLE IMPURITIES).................................. Meta-Fluoxetine HCl linearity at 0.05% - 1.0%........................................................................... Detection Limit for Fluoxetine HCl.............................................................................................. Quantitation Limit for Meta Fluoxetine HCl................................................................................ Accuracy for Meta-Fluoxetine HCl ............................................................................................ Method Repeatability for Meta-Fluoxetine HCl........................................................................... Intermediate Precision for Meta-Fluoxetine HCl......................................................................... SPECIFICITY - STABILITY INDICATING EVALUATION OF THE METHOD............................. FORCED DEGRADATION OF FINISHED PRODUCT AND STANDARD..................................1. Unstressed analysis...............................................................................................................2. Acid Hydrolysis stressed analysis..........................................................................................3. Base hydrolysis stressed analysis.........................................................................................4. Oxidation stressed analysis...................................................................................................5. Sunlight stressed analysis.....................................................................................................6. Heat of solution stressed analysis.........................................................................................7. Heat of powder stressed analysis.......................................................................................... System Suitability stressed analysis.......................................................................................... Placebo...................................................................................................................................... STABILITY OF STANDARD AND SAMPLE SOLUTIONS......................................................... Standard Solution...................................................................................................................... Sample Solutions....................................................................................................................... ROBUSTNESS.......................................................................................................................... Extraction................................................................................................................................... Factorial Design......................................................................................................................... CONCLUSION...........................................................................................................................ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationBACKGROUNDTherapeutically, Fluoxetine hydrochloride is a classified as a selective serotonin-reuptake inhibitor. Effectively used for the treatment of various depressions. Fluoxetine hydrochloride has been shown to have comparable efficacy to tricyclic antidepressants but with fewer anticholinergic side effects. The patent expiry becomes effective in 2001 (US). INTRODUCTIONFluoxetine capsules were prepared in two dosage strengths: 10mg and 20mg dosage strengths with the same capsule weight. The formulas are essentially similar and geometrically equivalent with the same ingredients and proportions. Minor changes in non-active proportions account for the change in active ingredient amounts from the 10 and 20 mg strength.The following validation, for the method SI-IAG-206-02 , includes assay and determination of Meta-Fluoxetine by HPLC, is based on the analytical method validation SI-IAG-209-06. Currently the method is the in-house method performed for Stability Studies. The Validation was performed on the 20mg dosage samples, IAG-21-001 and IAG-21-002.In the forced degradation studies, the two placebo samples were also used. PRECISIONSYSTEM REPEATABILITYFive replicate injections of the standard solution at the concentration of 0.4242mg/mL as described in method SI-IAG-206-02 were made and the relative standard deviation (RSD) of the peak areas was calculated.SAMPLE PEAK AREA#15390#25406#35405#45405#55406Average5402.7SD 6.1% RSD0.1ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::PRECISION - Method RepeatabilityThe full HPLC method as described in SI-IAG-206-02 was carried-out on the finished product IAG-21-001 for the 20mg dosage form. The method repeated six times and the relative standard deviation (RSD) was calculated.SAMPLENumber%ASSAYof labeled amountI 96.9II 97.8III 98.2IV 97.4V 97.7VI 98.5(%) Average97.7SD 0.6(%) RSD0.6PRECISION - Intermediate PrecisionThe full method as described in SI-IAG-206-02 was carried-out on the finished product IAG-21-001 for the 20mg dosage form. The method was repeated six times by a second analyst on a different day using a different HPLC instrument. The average assay and the relative standard deviation (RSD) were calculated.SAMPLENumber% ASSAYof labeled amountI 98.3II 96.3III 94.6IV 96.3V 97.8VI 93.3Average (%)96.1SD 2.0RSD (%)2.1The difference between the average results of method repeatability and the intermediate precision is 1.7%.HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationLINEARITYStandard solutions were prepared at 50% to 200% of the nominal concentration required by the assay procedure. Linear regression analysis demonstrated acceptability of the method for quantitative analysis over the concentration range required. Y-Intercept was found to be insignificant.RANGEDifferent concentrations of the sample (IAG-21-001) for the 20mg dosage form were prepared, covering between 50% - 200% of the nominal weight of the sample.Conc. (%)Conc. (mg/mL)Peak Area% Assayof labeled amount500.20116235096.7700.27935334099.21000.39734463296.61500.64480757797.52000.79448939497.9(%) Average97.6SD 1.0(%) RSD 1.0ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::RANGE (cont.)The results demonstrate linearity as well over the specified range.Correlation coefficient (RSQ)0.99981 Slope11808.3Y -Interceptresponse at 100%* 100 (%) 0.3%ACCURACYACCURACY OF STANDARD INJECTIONSFive (5) replicate injections of the working standard solution at concentration of 0.4242mg/mL, as described in method SI-IAG-206-02 were made.INJECTIONNO.PEAK AREA%ACCURACYI 539299.7II 540599.9III 540499.9IV 5406100.0V 5407100.0Average 5402.899.9%SD 6.10.1RSD, (%)0.10.1The percent deviation from the true value wasdetermined from the linear regression lineHPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::ACCURACY OF THE DRUG PRODUCTAdmixtures of non-actives (placebo, batch IAG-21-001 ) with Fluoxetine HCl were prepared at the same proportion as in a capsule (70%-180% of the nominal concentration).Three preparations were made for each concentration and the recovery was calculated.Conc.(%)Placebo Wt.(mg)Fluoxetine HCl Wt.(mg)Peak Area%Accuracy Average (%)70%7079.477.843465102.27079.687.873427100.77079.618.013465100.0101.0100%10079.6211.25476397.910080.8011.42491799.610079.6011.42485498.398.6130%13079.7214.90640599.413080.3114.75632899.213081.3314.766402100.399.618079.9920.10863699.318079.3820.45879499.418080.0820.32874899.599.4Placebo, Batch Lot IAG-21-001HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::VALIDATION OF FLUOXETINE HClAT LOW CONCENTRATIONLINEARITY AT LOW CONCENTRATIONSStandard solution of Fluoxetine were prepared at approximately 0.02%-1.0% of the working concentration required by the method SI-IAG-206-02. Linear regression analysis demonstrated acceptability of the method for quantitative analysis over this range.ACCURACY OF FLUOXETINE HCl AT LOW CONCENTRATIONThe peak areas of the standard solution at the working concentration were measured and the percent deviation from the true value, as determined from the linear regression was calculated.SAMPLECONC.µg/100mLAREA FOUND%ACCURACYI 470.56258499.7II 470.56359098.1III 470.561585101.3IV 470.561940100.7V 470.56252599.8VI 470.56271599.5(%) AverageSlope = 132.7395299.9SD Y-Intercept = -65.872371.1(%) RSD1.1HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSystem RepeatabilitySix replicate injections of standard solution at 0.02% and 0.05% of working concentration as described in method SI-IAG-206-02 were made and the relative standard deviation was calculated.SAMPLE FLUOXETINE HCl AREA0.02%0.05%I10173623II11503731III10103475IV10623390V10393315VI10953235Average10623462RSD, (%) 5.0 5.4Quantitation Limit - QLThe quantitation limit ( QL) was established by determining the minimum level at which the analyte was quantified. The quantitation limit for Fluoxetine HCl is 0.02% of the working standard concentration with resulting RSD (for six injections) of 5.0%. Detection Limit - DLThe detection limit (DL) was established by determining the minimum level at which the analyte was reliably detected. The detection limit of Fluoxetine HCl is about 0.01% of the working standard concentration.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::VALIDATION FOR META-FLUOXETINE HCl(EVALUATING POSSIBLE IMPURITIES)Meta-Fluoxetine HCl linearity at 0.05% - 1.0%Relative Response Factor (F)Relative response factor for Meta-Fluoxetine HCl was determined as slope of Fluoxetine HCl divided by the slope of Meta-Fluoxetine HCl from the linearity graphs (analysed at the same time).F =132.7395274.859534= 1.8Detection Limit (DL) for Fluoxetine HClThe detection limit (DL) was established by determining the minimum level at which the analyte was reliably detected.Detection limit for Meta Fluoxetine HCl is about 0.02%.Quantitation Limit (QL) for Meta-Fluoxetine HClThe QL is determined by the analysis of samples with known concentration of Meta-Fluoxetine HCl and by establishing the minimum level at which the Meta-Fluoxetine HCl can be quantified with acceptable accuracy and precision.Six individual preparations of standard and placebo spiked with Meta-Fluoxetine HCl solution to give solution with 0.05% of Meta Fluoxetine HCl, were injected into the HPLC and the recovery was calculated.HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::META-FLUOXETINE HCl[RECOVERY IN SPIKED SAMPLES].Approx.Conc.(%)Known Conc.(µg/100ml)Area in SpikedSampleFound Conc.(µg/100mL)Recovery (%)0.0521.783326125.735118.10.0521.783326825.821118.50.0521.783292021.55799.00.0521.783324125.490117.00.0521.783287220.96996.30.0521.783328526.030119.5(%) AVERAGE111.4SD The recovery result of 6 samples is between 80%-120%.10.7(%) RSDQL for Meta Fluoxetine HCl is 0.05%.9.6Accuracy for Meta Fluoxetine HClDetermination of Accuracy for Meta-Fluoxetine HCl impurity was assessed using triplicate samples (of the drug product) spiked with known quantities of Meta Fluoxetine HCl impurity at three concentrations levels (namely 80%, 100% and 120% of the specified limit - 0.05%).The results are within specifications:For 0.4% and 0.5% recovery of 85% -115%For 0.6% recovery of 90%-110%HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::META-FLUOXETINE HCl[RECOVERY IN SPIKED SAMPLES]Approx.Conc.(%)Known Conc.(µg/100mL)Area in spikedSample Found Conc.(µg/100mL)Recovery (%)[0.4%]0.4174.2614283182.66104.820.4174.2614606187.11107.370.4174.2614351183.59105.36[0.5%]0.5217.8317344224.85103.220.5217.8316713216.1599.230.5217.8317341224.81103.20[0.6%]0.6261.3918367238.9591.420.6261.3920606269.81103.220.6261.3920237264.73101.28RECOVERY DATA DETERMINED IN SPIKED SAMPLESHPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::REPEATABILITYMethod Repeatability - Meta Fluoxetine HClThe full method (as described in SI-IAG-206-02) was carried out on the finished drug product representing lot number IAG-21-001-(1). The HPLC method repeated serially, six times and the relative standard deviation (RSD) was calculated.IAG-21-001 20mg CAPSULES - FLUOXETINESample% Meta Fluoxetine % Meta-Fluoxetine 1 in Spiked Solution10.0260.09520.0270.08630.0320.07740.0300.07450.0240.09060.0280.063AVERAGE (%)0.0280.081SD 0.0030.012RSD, (%)10.314.51NOTE :All results are less than QL (0.05%) therefore spiked samples with 0.05% Meta Fluoxetine HCl were injected.HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationED. N0: 04Effective Date:APPROVED::Intermediate Precision - Meta-Fluoxetine HClThe full method as described in SI-IAG-206-02 was applied on the finished product IAG-21-001-(1) .It was repeated six times, with a different analyst on a different day using a different HPLC instrument.The difference between the average results obtained by the method repeatability and the intermediate precision was less than 30.0%, (11.4% for Meta-Fluoxetine HCl as is and 28.5% for spiked solution).IAG-21-001 20mg - CAPSULES FLUOXETINESample N o:Percentage Meta-fluoxetine% Meta-fluoxetine 1 in spiked solution10.0260.06920.0270.05730.0120.06140.0210.05850.0360.05560.0270.079(%) AVERAGE0.0250.063SD 0.0080.009(%) RSD31.514.51NOTE:All results obtained were well below the QL (0.05%) thus spiked samples slightly greater than 0.05% Meta-Fluoxetine HCl were injected. The RSD at the QL of the spiked solution was 14.5%HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSPECIFICITY - STABILITY INDICATING EVALUATIONDemonstration of the Stability Indicating parameters of the HPLC assay method [SI-IAG-206-02] for Fluoxetine 10 & 20mg capsules, a suitable photo-diode array detector was incorporated utilizing a commercial chromatography software managing system2, and applied to analyze a range of stressed samples of the finished drug product.GLOSSARY of PEAK PURITY RESULT NOTATION (as reported2):Purity Angle-is a measure of spectral non-homogeneity across a peak, i.e. the weighed average of all spectral contrast angles calculated by comparing all spectra in the integrated peak against the peak apex spectrum.Purity Threshold-is the sum of noise angle3 and solvent angle4. It is the limit of detection of shape differences between two spectra.Match Angle-is a comparison of the spectrum at the peak apex against a library spectrum.Match Threshold-is the sum of the match noise angle3 and match solvent angle4.3Noise Angle-is a measure of spectral non-homogeneity caused by system noise.4Solvent Angle-is a measure of spectral non-homogeneity caused by solvent composition.OVERVIEWT he assay of the main peak in each stressed solution is calculated according to the assay method SI-IAG-206-02, against the Standard Solution, injected on the same day.I f the Purity Angle is smaller than the Purity Threshold and the Match Angle is smaller than the Match Threshold, no significant differences between spectra can be detected. As a result no spectroscopic evidence for co-elution is evident and the peak is considered to be pure.T he stressed condition study indicated that the Fluoxetine peak is free from any appreciable degradation interference under the stressed conditions tested. Observed degradation products peaks were well separated from the main peak.1® PDA-996 Waters™ ; 2[Millennium 2010]ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationFORCED DEGRADATION OF FINISHED PRODUCT & STANDARD 1.UNSTRESSED SAMPLE1.1.Sample IAG-21-001 (2) (20mg/capsule) was prepared as stated in SI-IAG-206-02 and injected into the HPLC system. The calculated assay is 98.5%.SAMPLE - UNSTRESSEDFluoxetine:Purity Angle:0.075Match Angle:0.407Purity Threshold:0.142Match Threshold:0.4251.2.Standard solution was prepared as stated in method SI-IAG-206-02 and injected into the HPLC system. The calculated assay is 100.0%.Fluoxetine:Purity Angle:0.078Match Angle:0.379Purity Threshold:0.146Match Threshold:0.4272.ACID HYDROLYSIS2.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as in method SI-IAG-206-02 : An amount equivalent to 20mg Fluoxetine was weighed into a 50mL volumetric flask. 20mL Diluent was added and the solution sonicated for 10 minutes. 1mL of conc. HCl was added to this solution The solution was allowed to stand for 18 hours, then adjusted to about pH = 5.5 with NaOH 10N, made up to volume with Diluent and injected into the HPLC system after filtration.Fluoxetine peak intensity did NOT decrease. Assay result obtained - 98.8%.SAMPLE- ACID HYDROLYSISFluoxetine peak:Purity Angle:0.055Match Angle:0.143Purity Threshold:0.096Match Threshold:0.3712.2.Standard solution was prepared as in method SI-IAG-206-02 : about 22mg Fluoxetine HCl were weighed into a 50mL volumetric flask. 20mL Diluent were added. 2mL of conc. HCl were added to this solution. The solution was allowed to stand for 18 hours, then adjusted to about pH = 5.5 with NaOH 10N, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity did NOT decrease. Assay result obtained - 97.2%.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSTANDARD - ACID HYDROLYSISFluoxetine peak:Purity Angle:0.060Match Angle:0.060Purity Threshold:0.099Match Threshold:0.3713.BASE HYDROLYSIS3.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as per method SI-IAG-206-02 : An amount equivalent to 20mg Fluoxetine was weight into a 50mL volumetric flask. 20mL Diluent was added and the solution sonicated for 10 minutes. 1mL of 5N NaOH was added to this solution. The solution was allowed to stand for 18 hours, then adjusted to about pH = 5.5 with 5N HCl, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity did NOT decrease. Assay result obtained - 99.3%.SAMPLE - BASE HYDROLYSISFluoxetine peak:Purity Angle:0.063Match Angle:0.065Purity Threshold:0.099Match Threshold:0.3623.2.Standard stock solution was prepared as per method SI-IAG-206-02 : About 22mg Fluoxetine HCl was weighed into a 50mL volumetric flask. 20mL Diluent was added. 2mL of 5N NaOH was added to this solution. The solution was allowed to stand for 18 hours, then adjusted to about pH=5.5 with 5N HCl, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity did NOT decrease - 99.5%.STANDARD - BASE HYDROLYSISFluoxetine peak:Purity Angle:0.081Match Angle:0.096Purity Threshold:0.103Match Threshold:0.3634.OXIDATION4.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as per method SI-IAG-206-02. An equivalent to 20mg Fluoxetine was weighed into a 50mL volumetric flask. 20mL Diluent added and the solution sonicated for 10 minutes.1.0mL of 30% H2O2 was added to the solution and allowed to stand for 5 hours, then made up to volume with Diluent, filtered and injected into HPLC system.Fluoxetine peak intensity decreased to 95.2%.ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSAMPLE - OXIDATIONFluoxetine peak:Purity Angle:0.090Match Angle:0.400Purity Threshold:0.154Match Threshold:0.4294.2.Standard solution was prepared as in method SI-IAG-206-02 : about 22mg Fluoxetine HCl were weighed into a 50mL volumetric flask and 25mL Diluent were added. 2mL of 30% H2O2 were added to this solution which was standing for 5 hours, made up to volume with Diluent and injected into the HPLC system.Fluoxetine peak intensity decreased to 95.8%.STANDARD - OXIDATIONFluoxetine peak:Purity Angle:0.083Match Angle:0.416Purity Threshold:0.153Match Threshold:0.4295.SUNLIGHT5.1.Sample solution of IAG-21-001 (2) (20mg/capsule) was prepared as in method SI-IAG-206-02 . The solution was exposed to 500w/hr. cell sunlight for 1hour. The BST was set to 35°C and the ACT was 45°C. The vials were placed in a horizontal position (4mm vials, National + Septum were used). A Dark control solution was tested. A 2%w/v quinine solution was used as the reference absorbance solution.Fluoxetine peak decreased to 91.2% and the dark control solution showed assay of 97.0%. The difference in the absorbance in the quinine solution is 0.4227AU.Additional peak was observed at RRT of 1.5 (2.7%).The total percent of Fluoxetine peak with the degradation peak is about 93.9%.SAMPLE - SUNLIGHTFluoxetine peak:Purity Angle:0.093Match Angle:0.583Purity Threshold:0.148Match Threshold:0.825 ED. N0: 04Effective Date:APPROVED::HPLC ASSAY with DETERMINATION OF META-FLUOXETINE HCl.ANALYTICAL METHOD VALIDATION10 and 20mg Fluoxetine Capsules HPLC DeterminationSUNLIGHT (Cont.)5.2.Working standard solution was prepared as in method SI-IAG-206-02 . The solution was exposed to 500w/hr. cell sunlight for 1.5 hour. The BST was set to 35°C and the ACT was 42°C. The vials were placed in a horizontal position (4mm vials, National + Septum were used). A Dark control solution was tested. A 2%w/v quinine solution was used as the reference absorbance solution.Fluoxetine peak was decreased to 95.2% and the dark control solution showed assay of 99.5%.The difference in the absorbance in the quinine solution is 0.4227AU.Additional peak were observed at RRT of 1.5 (2.3).The total percent of Fluoxetine peak with the degradation peak is about 97.5%. STANDARD - SUNLIGHTFluoxetine peak:Purity Angle:0.067Match Angle:0.389Purity Threshold:0.134Match Threshold:0.8196.HEAT OF SOLUTION6.1.Sample solution of IAG-21-001-(2) (20 mg/capsule) was prepared as in method SI-IAG-206-02 . Equivalent to 20mg Fluoxetine was weighed into a 50mL volumetric flask. 20mL Diluent was added and the solution was sonicated for 10 minutes and made up to volume with Diluent. 4mL solution was transferred into a suitable crucible, heated at 105°C in an oven for 2 hours. The sample was cooled to ambient temperature, filtered and injected into the HPLC system.Fluoxetine peak was decreased to 93.3%.SAMPLE - HEAT OF SOLUTION [105o C]Fluoxetine peak:Purity Angle:0.062Match Angle:0.460Purity Threshold:0.131Match Threshold:0.8186.2.Standard Working Solution (WS) was prepared under method SI-IAG-206-02 . 4mL of the working solution was transferred into a suitable crucible, placed in an oven at 105°C for 2 hours, cooled to ambient temperature and injected into the HPLC system.Fluoxetine peak intensity did not decrease - 100.5%.ED. N0: 04Effective Date:APPROVED::。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
Granzyme and indirect cleavage of extracellular chronic low-dose ultravioletIntroductionAging is a complex and time-dependent biological process that affects allorgan systems and is characterized by a decline in function and areduced ability of the body to respond to stress due to physical,biological,and chemical agents.As the average age of the Westernpopulation increases,with predictions for individuals aged60years orolder to account for26%of the population in the USA by the year2050(Administration on Aging,2010),aging and age-related diseases arebecoming a growing issue and problem.Chronic low-grade inflammation and oxidative stress have beenproposed as causative agents of aging and age-related disease(Hendelet al.,2010;Chung et al.,2011).The skin represents an ideal modelorgan for aging research because of its accessibility,thus allowing thestudy of intrinsic and extrinsic/environmental factors contributing to thecomplex phenomenon of aging,injury,and repair(Wenk et al.,2001).Among all the environmental factors,solar UV irradiation is the mostinfluential in premature aging of the skin,causing80–90%of themorphological,structural,and biochemical changes collectively termedphotoaging(Gilchrest&Krutmann,2006).Chronically irradiated skin ismetabolically hyperactive and is characterized by epidermal hyperplasia,reduced/disorganized collagen,and enhanced inflammation(Bossetet al.,2003).Over recent years,substantial progress has been made in elucidatingthe underlying molecular mechanisms of UV-induced photoaged skin.Itis generally accepted that UVB(280–320nm)and UVA(320–400nm)irradiation generate severe oxidative stress in skin cells,resulting intransient and permanent genetic damage,increased AP-1activity,increased MMP expression,impaired TGF-b signaling,enhanced collagendegradation,and decreased collagen synthesis(Pillai et al.,2005;Gilchrest&Krutmann,2006).Granzyme B(GzmB)is a serine protease that has been traditionallystudied in immune cell-mediated apoptosis,once believed to bereleased exclusively from cytotoxic lymphocytes and natural killer cells,along with the pore-forming protein perforin,to induce apoptotic celldeath(Jenne&Tschopp,1988).However,recent work has focusedon extracellular GzmB due to emerging evidence that GzmBaccumulates in the extracellular milieu and/or bodyfluids of manyage-related or inflammatory diseases,and retains its activity(Boivinet al.,2009).It is now known that GzmB can be released constitu-tively and nonspecifically to the extracellular space by lymphocytesand NK cells in the absence of target cell engagement and can beinduced in many other types of immune(e.g.,mast cells,basophils,dendritic cells,B cells)and nonimmune cells(e.g.,keratinocytes,chondrocytes)that often do not express perforin or form immuno-logical synapses with target cells(Pardo et al.,2007;Boivin et al.,2009;Prakash et al.,2009).Of particular relevance to the skin andUV irradiation,both UVA and UVB irradiation induce GzmB expressionin keratinocytes,both in vitro and in human skin(Hernandez-Pigeonet al.,2006,2007).Many extracellular matrix proteins are substratesof GzmB(Buzza et al.,2005;Hendel et al.,2010;Boivin et al.,2012),including decorin andfibronectin,which have important roles in&Sons Ltd.License,which permits use, cited.1 Doi:10.1111/acel.12298collagenfibrillogenesis and integrity,and cell attachment and signal-ing,respectively(Danielson et al.,1997;Romberger,1997;Geng et al.,2006).Furthermore,a role of GzmB has emerged in derma-tological indications with studies implicating extracellular GzmB activity in diet-induced models of skin aging and impaired wound healing (Hiebert et al.,2011,2013;Hsu et al.,2014).In these studies,GzmB deficiency protected against a loss in dermal collagen density and skin thinning,and accelerated wound closure.As greater than80%of skin aging is believed to be due to UV exposure(Gilchrest&Krutmann,2006),and GzmB is expressed by many of the cells present or recruited after irradiation,we hypothesized that GzmB contributes to extracellular matrix degradation after UV irradiation through both direct cleavage of ECM proteins and indirectly through the induction of other proteinases,which leads to a phenotype of aged skin. Using a mouse model of chronic,low-grade UV irradiation over 20weeks,we demonstrated that GzmB deficiency protects against wrinkle formation and a loss in collagen density,while GzmB-mediated fibronectin and decorin cleavage contributed to increased MMP expres-sion and collagen degradation.This work demonstrates an important role for GzmB in aging skin,which may have implications in many other aged-related chronic inflammatory diseases where ECM degradation is a hallmark.ResultsGzmB deficiency protects against wrinkle formationWild-type(WT)and GzmB-knockout(GzmB-KO)mice were repeatedly exposed to solar-simulated UV irradiation(UVR)for20weeks.Repre-sentative digital images of mice after the20week treatment period are shown in Fig.1A.Each mouse in the study was scored on a scale of UV damage by three independent assessors blinded to time,genotype,and treatment(Fig.1B;results expressed at median values for each scorer). Over the course of the20-week study,WT and GzmB-KO nonirradiated control mice had no visible changes in skin appearance,achieving an expected score of0.By week7,both WT and GzmB-KO mice exposed to UV developed dark-pigmented spots over their mid-dorsum.After 20weeks of UV exposure,there was a significant difference in the appearance of wrinkles between WT and GzmB-KO mice,with GzmB deficiency protecting against the formation of deep,coarse wrinkles (Fig1).Increased GzmB expression in UV-irradiated skinFollowing20weeks UV irradiation,dorsal skin samples were collected and GzmB expression was assessed via -pared to wild-type nonirradiated control animals(WT-C),UV-treated skin(WT-UVR)exhibited a marked increase in GzmB expression withboth intracellular and extracellular staining(Fig.2A).Increased staining was observed in the keratinocytes of the epidermis as well as in the epithelial cells of hair follicles.A large cellular infiltrate also stained positively for GzmB.These cells,determined to be mast cells (see next section),had intact and degranulated phenotypes,in which GzmB appeared to be released from the cell(Fig.2A,WT-UVR, insert).Histological analyses of skin from UV-treated animals showed typical morphological changes associated with chronic UV exposure.There was a significant increase in epidermal and dermal thicknesses in both WT and GzmB-KO mice,leading to an overall increase in skin thickness(Fig. S1).GzmB colocalizes to an increased mast cell populationMast cells were visualized and quantified in mouse skin samples using toluidine blue(TBO)staining(pH=2).There was a significant increase in the number of mast cells in the skin of both WT and GzmB-KO mice after UV exposure as compared to control mice(WT-C17.3Æ1.0;WT-UVR 31.8Æ1.3;KO-UVR29.7Æ1.0;KO-C19.2Æ2.5cells/mm;Fig.2B) The concomitant increase in mast cells in both genotypes along with similar increases in skin thickness indicates that GzmB deficiency did not affect the immune cell recruitment and tissue response after UV exposure and that GzmB deficiency had no adverse affects on these processes.This is supported by the quantification of other immune cells(A)(B)Fig.1GzmB deficiency protects against wrinkle formation.(A)Representative images of wild-type(WT)and GzmB-knockout mice(KO)exposed to chronic low-grade UV irradiation(UVR)for20weeks.Nonirradiated controls were included for comparison.(B)Three independent scorers blinded to time,genotype,and treatment assessed each mouse,and results are presented as median scores for each scorer(*P<0.05,Wilcoxon signed rank).GzmB degrades ECM after chronic UV irradiation,L.G.Parkinson et al.2ª2014The Authors.Aging Cell published by the Anatomical Society and John Wiley&Sons Ltd.(neutrophils,macrophages,T cells),which showed similar results (Fig.S2).Many of the GzmB positively stained cells had a mast cell phenotype (Fig.2A).To investigate the colocalization of GzmB to mast cells,skin sections were first stained with TBO for mast cells.Subsequently,sections were immunostained for GzmB.A direct colocalization of GzmB immunopositivity with mast cells in wild-type control and UV-exposed animals was observed (Fig.2C).GzmB deficiency protects against loss of dermal collagen density and fibronectin degradation in UV-irradiated skinLoss of dermal collagen density and organization is a hallmark of chronically aged skin and contributes to macroscopic changes in skin appearance (Fisher et al.,1997).Collagen density in mouse skinsamples was examined by picrosirius red staining,and multiphoton microscopy.Picrosirius red staining was observed under polarized light,and dermal collagen from wild-type control (WT-C),GzmB-KO control (KO-C),and GzmB-KO UV-irradiated (KO-UVR)mice exhibited bright red/orange staining indicative of thick,dense collagen fibres at the 20-week time point.In contrast,there was a diminished intensity of staining of dermal collagen in the skin of wild-type UV-irradiated mice (WT-UVR),and collagen bundles appeared to be less tightly packed (Fig.3A).Quantification of the intensity of staining revealed a significant decrease for wild-type UV-irradiated mice compared to all other groups (%of WT-C:WT-UVR 79Æ4%;KO-UVR 100Æ3%;KO-C 108Æ10%;Fig.3A).Representative second-harmonic generation (SHG)images originat-ing from the collagen matrix are shown in Fig.3B.There was a significant reduction in signal and collagen density from wild-type(A)(B)(C)Fig.2Increased GzmB expression and mast cells in UV-irradiated skin.(A)Dorsal skin sections from nonirradiated (WT-C)and UV-irradiated (WT-UVR)mice immunostained for GzmB.Insert –magnified view of degranulating cell with GzmB immunopositivity.Scale bars =100l m.(B)Dorsal skin sections from both nonirradiated (C)and UV-treated (UVR),wild-type (WT),and granzyme B-knockout (KO)mice were stained with TBO,and the number of mast cells was counted (mean ÆSEM;***P <0.001Tukey’smultiple comparison).Scale bars =60l m.(C)Direct colocalization of GzmBimmunopositivity with mast cells.Sections were first stained with TBO (pH =2),and the same sections were thenimmunostained for GzmB following image capture.Scale bars =60l m.GzmB degrades ECM after chronic UV irradiation,L.G.Parkinson et al.3ª2014The Authors.Aging Cell published by the Anatomical Society and John Wiley &Sons Ltd.control to wild-type UV-irradiated mice (34Æ4%of WT-C),which was significantly protected in GzmB-KO UV-irradiated mice (58Æ6%of WT-C)(Fig.3B).GzmB cleavage of human and mouse fibronectin (FN)has been observed in multiple in vitro and in vivo studies (Buzza et al.,2005;Hernandez-Pigeon et al.,2007;Hendel &Granville,2013;Hiebert et al.,2013).In this study,UV irradiation induced a significant loss of full-length FN in skin tissue of wild-type mice (56Æ6%of WT-C;n =6)as compared to controls.However,skin from GzmB-KO mice also exposed to UV had similar levels of FN to controls (95Æ16%of WT-C;n =6),suggesting there was protection from FN cleavage and degradation in GzmB-deficient mice.GzmB causes fibroblast detachment and fibronectin fragmentation in vitroTo rationalize the observations of loss of collagen density in vivo ,the effect of extracellular GzmB on fibroblast function and FN fragmentation was investigated in vitro .In support of previous studies with other cell types (Buzza et al.,2005;Pardo et al.,2007),recombinant GzmB treatment caused a dramatic change in morphology of 3T3mouse fibroblasts.Cells rounded up and were observed to detach from culture plates.GzmB treatment resulted in a dose-dependent decrease in the number of adhered cells which was abrogated by cotreatment with Compound 20(specific GzmB inhibitor)(Fig.4A).(A)(C)(B)Fig.3GzmB deficiency protects against loss of dermal collagen density andfibronectin in UV-irradiated skin.(A)Dorsal skin sections were stained with picrosirius red and visualized under polarized light.Quantification of collagen was achieved by color segmentation and intensity analysis of stained sections.Scale bars =100l m.(B)Second-harmonic generation signals of collagen from intact ex vivo skin samples were quantified as a measure of collagen density.Scale bars =20l m (*P <0.05;**P <0.01;***P <0.001Tukey’s multiple comparison).(C)Fibronectin was assessed in tissue homogenates via Western blot.Results are presented as a percentage of wild-type nonirradiated control (WT-C)(mean ÆSEM;*P <0.05Dunnett’s multiple comparison).GzmB degrades ECM after chronic UV irradiation,L.G.Parkinson et al.4ª2014The Authors.Aging Cell published by the Anatomical Society and John Wiley &Sons Ltd.In parallel experiments,supernatants were collected from all wells and aliquot samples were prepared for separation on SDS-PAGE gels and probed for FN by Western blot.GzmB treatment resulted in a dose-dependent increase in FN fragmentation,which was inhibited by cotreatment with the specific GzmB inhibitor,Compound20(Fig.4B). These fragments were assayed from the supernatant(treatment in serum-free media)and thus can be assumed to be released from the cell-derived matrix.GzmB-mediated FN fragments increase MMP expression in fibroblastsPrimaryfibroblasts were added to culture wells coated with FN. Experimental wells coated with FN werefirst treated with GzmB for 2h to produce GzmB-mediated FN fragments both in the supernatant and attached to the culture plate(data not shown)(Hendel&Granville, 2013).After inhibition of GzmB with Compound20,primaryfibroblasts were seeded to wells and incubated for20h,after which supernatants were collected and assayed for MMP-1by Western blot.There was a significant increase in the expression and release of MMP-1from fibroblasts in contact with GzmB-mediated FN fragments compared to controls with intact FN(151Æ10%of FN control;Fig.4C).Similarly, there was a significant increase in the amount of MMP-3released to the supernatant(129.1Æ10%of FN control;Fig.S3).Skin sections from control and UV-irradiated mice at20weeks were immunostained for MMP-1(Fig.4D).There was intense staining in both the epidermis and hair follicles,which were similar for all control and UV-irradiated mice.However,there was a noticeable difference in the(C)(B)(A)(D)Fig.4GzmB causesfibroblast detachment andfibronectin fragmentation in vitro,and GzmB-mediated FN fragments induce MMP-1expression infibroblasts.(A)Mousefibroblasts plated overnight in complete medium were treated with the indicated concentrations of GzmBÆInhibitor(I;50l M)for7h(in serum-free conditions).Adherent cells were assessed by MTS assay after washing once in PBS to remove nonadherent cells(meanÆSEM from quadruplicate wells;***P<0.001Dunnett’s multiple comparison).(B)Supernatants collected from(A)were assayed forfibronectin by Western blot.Closed arrowhead=full-lengthfibronectin;open arrowhead=fibronectin fragments.Although the same blot,the dotted line represents sections presented at different brightness/contrast so that fragments can be clearly observed at different kDa. (C)Primaryfibroblasts were added to GzmB-mediated FN fragments,and MMP-1release was assayed in the supernatants after20h by Western blot.GAPDH probed from cell lysates of the same wells served as loading controls.Results are presented as a percentage of intactfibronectin control(meanÆSEM from quadruplicate wells,**P<0.01t-test).(D)Dorsal skin sections from mice were stained with MMP-1antibody,and intensity of staining in the dermis(excluding hair follicles)was measured by detecting the number of positive pixels above a set threshold,normalized to area.Results are expressed as a percentage of wild-type control(WT-C)(meanÆSEM).Scale bars=60l m.GzmB degrades ECM after chronic UV irradiation,L.G.Parkinson et al.5ª2014The Authors.Aging Cell published by the Anatomical Society and John Wiley&Sons Ltd.expression of MMP-1in the dermis,which exhibited both intracellular and extracellular staining.While it failed to reach statistical significance, quantification of the intensity of staining in the dermis(excluding hair follicles)revealed a trend for an increase in the amount of MMP-1in wild-type UV-irradiated mice,which was not observed in GzmB-KO UV-irradiated mice(Fig.4D).GzmB-mediated decorin cleavage renders collagenfibrils more susceptible to degradation by MMP-1Decorin interacts with the surface of collagenfibrils to impede access and proteolytic cleavage by collagenous proteinases(Geng et al.,2006). In the present study,GzmB-mediated decorin cleavage rendered collagenfibrils more susceptible to degradation by MMP-1(Fig.5). GzmB cleaves decorin(Fig.5A).There was a significant decrease in decorin staining in the skin of wild-type UV-irradiated mice(24Æ8%of WT-C)as compared to wild-type control mice,which was significantly protected in GzmB-KO UV-irradiated mice(57Æ9%of WT-C)(Fig.5B). Decorin attenuated MMP-1-mediated collagen cleavage(Fig.5C). However,treatment of the decorin-coated collagenfibrils with GzmB significantly increased the amount of collagen degradation to levels observed without decorin.GzmB alone did not cleave collagenfibrils (data not shown).Addition of Compound20inhibited the proteolytic activity of GzmB and thus protected decorin from cleavage,and in turn protected the collagenfibrils from MMP-1proteolysis(Fig.5C).DiscussionAmong all the organs,the study of skin is of particular importance because it is crucial to maintaining homeostasis in the body and has a strong societal impact due to its visibility,and it represents an ideal model organ for aging research(Wenk et al.,2001;Gilchrest& Krutmann,2006).In contrast to intrinsically aged skin,which shows an overall reduction in cell numbers,UV-photoaged skin is characterized by epidermal hyperplasia and an increase in the number of dermal fibroblasts,mast cells,macrophages,and T cells(Bosset et al.,2003; Iddamalgoda et al.,2008).This infiltrate is indicative of a chronic inflammatory phenotype.Mast cells have a major role in the develop-ment of skin inflammatory processes.Cell-to-cell communications between mast cells andfibroblasts,as well as evidence of mast cell degranulation at sites of chronic inflammation have been documented (Metz et al.,2007).We observed an increase in epidermal thickness and mast cells in UV-irradiated skin.Immunostaining for GzmB revealed a direct colocalization of GzmB with the mast cell infiltrate,which supports previous studies demonstrating that mouse and human mast cells produce GzmB in vivo and in vitro and release it upon activation(Pardo et al.,2007;Strik et al.,2007).In addition,we observed increased GzmB expression in the keratinocytes of the epidermis after UV irradiation,also in line with previous reports(Hernandez-Pigeon et al.,2006,2007). Aside from other possible inflammatory infiltrates expressing GzmB(e.g., cytotoxic lymphocytes),this represents a significant source of GzmB that may be released to the extracellular space and contribute to ECM degradation.Other studies comparing potential GzmB activity to neutrophil elastase in skin after UV irradiation have overlooked these important other sources(Li et al.,2013).Overall,GzmB is highly expressed after UV irradiation and may be a significant contributor to UV-induced ECM degradation,as well as in other pathologies charac-terized by chronic inflammation and ECM degradation.Chronically irradiated skin is characterized by alterations in the dermal connective tissue.The ECM in the dermis mainly consists of collagen,elastin,proteoglycans(e.g.,decorin),andfibronectin.In particular,collagenfibrils are important for the strength and resilience of skin,and alterations in their number and structure are thought to be responsible for wrinkle formation(Gilchrest&Krutmann,2006).In the present study,using a mouse model of chronic UV irradiation over 20weeks,GzmB deficiency significantly reduced the formation of deep coarse wrinkles and protected against the loss of collagen density in UV-treated skin.The natural bifringent properties of collagen were exploited to analyze collagen structure,organization, and density in unfixed,unstained,and thick skin samples in three-dimensional space using multiphoton microscopy.Highly ordered fibril-forming collagens produce second-harmonic generation(SHG) signals without the need for any exogenous label or processing,which correlate with the density and organization of the collagen matrix (Palero et al.,2007;Abraham et al.,2010).We suggest the results obtained using this technique are more robust and provide a better representation of the collagen density in the associated groups than picrosirius red staining,as while the analysis offixed,thin-sliced sections may provide information in regard to content and morpho-logical structure,important3-dimensional and organizational features and properties may be overlooked or changed during processing.In addition,while we hypothesize that GzmB may be contributing to ECM degradation and result in a loss of collagen density,it is unlikely that a deficiency or inhibition of GzmB would be totally protective(as suggested by the picrosirius red staining).Other well-characterized processes,such as MMP induction and direct collagen degradation, may still occur,and the results obtained with multiphoton and SHG adequately reflect this physiology.Overall,our results provide evidence that GzmB deficiency protects against the loss of collagen density and the formation of deep wrinkles after UV irradiation,suggesting that GzmB contributes to collagen degradation and the appearance of photoaged skin.As GzmB does not directly cleave collagen,we explored mechanisms to rationalize the differences in collagen density between GzmB-KO and wild-type mice.GzmB cleavesfibronectin(Buzza et al.,2005),and there was a significant difference in the amount of full-lengthfibronectin(FN) in skin homogenates of UV-treated skin.The quantification of a greater amount of full-length FN in GzmB-KO mouse skin is assumed to be due to the lack of cleavage by GzmB.Unfortunately,a limitation in the current study is in the ability to detectfibronectin fragments in vivo,as data showing a reduction infibronectin fragments in GzmB-KO UV-irradiated skin would support this assumption.However,due to the relative protein load of a total skin homogenate,it is difficult to observe these fragments on Western blot.However,to further support our findings,GzmB treatment of mousefibroblasts in culture resulted in a dose-dependent increase in FN fragmentation from the cell-derived matrix.FN is an important multifunctional ECM protein,containing an RGD integrin-binding site that facilitates cell binding and migration (Romberger,1997).Previous studies suggest that GzmB cleaves FN just after the RGD-binding domain,implying that GzmB-mediated FN proteolysis may alter cell–matrix interactions(Buzza et al.,2005).In the present study,we observed a dose-dependent increase in cell rounding and detachment(after washing)following GzmB treatment that was accompanied by an increase in free FN fragments in the supernatant.FN fragments have been identified in the bodilyfluids of many chronic inflammatory diseases,and it has been shown that exposure to certain FN fragments can significantly alter cell behavior, triggering different events from those elicited by binding of native fibronectin(Werb et al.,1989;Stanley et al.,2008).Of particular relevance,it is known that FN fragments can increase the expression ofGzmB degrades ECM after chronic UV irradiation,L.G.Parkinson et al.6ª2014The Authors.Aging Cell published by the Anatomical Society and John Wiley&Sons Ltd.MMPs infibroblasts(Werb et al.,1989;Huhtala et al.,1995;Tremble et al.,1995;Kapila et al.,1996).These studies have shown that rabbit synovialfibroblasts express basal levels of MMP-1and MMP-3when plated on intact FN,but elevated levels when plated on FN fragments containing the RGD cell-binding domain.They suggest the particular fragment modulates the expression of MMP-1via its binding with the a5b1integrin receptor,inducing a signaling cascade involving the AP-1 and PEA-3elements on the MMP-1promoter(AP-1is also common to the MMP-3promoter)(Tremble et al.,1995).Meanwhile,intact FN allows for cooperative signaling with multiple integrins outside this domain,which suppresses the induction(Huhtala et al.,1995).In our study,direct GzmB-mediated FN fragmentation increased the expression and release of MMP-1and MMP-3from human dermalfibroblasts.An increase in MMP-1staining was also observed in skin from wild-type UV-irradiated mice.While it is possible that the induction of MMPs occurs through similar signaling pathways,further work is needed to support this hypothesis.Overall,while the induction of MMPs and the cleavage of collagen are well described in UV-irradiated skin(Gilchrest& Krutmann,2006),GzmB may further mediate the expression through FN fragmentation to result in more collagen degradation as observed in our model.There have been many studies exploring the role of topical tretinoin (retinoic acid)administration to improve the appearance of photoaged skin,which is reported to inhibit the induction of MMP-1,MMP-3,and MMP-9in both the epidermis and dermis of skin exposed to UV irradiation(Griffiths et al.,1992;Fisher et al.,1997).Although they have shown promise in treatment of skin aging,irritant reactions such as burning,scaling,or dermatitis associated with retinoid therapy limit their acceptance by patients(Mukherjee et al.,2006).In addition,it is now recognized that MMPs are essential for the regulation of many normal physiological processes and that broad inhibition of MMPs may promote inflammation by suppressing MMP-mediated chemokine regulation (Murphy&Nagase,2008;Dufour&Overall,2013).In fact,it is now believed that10of the24MMPs have anti-inflammatory or antitumor-igenic roles and have been termed drug‘antitargets,’meaning that the beneficial function of these enzymes should not be inhibited(Dufour& Overall,2013).It follows that extracellular GzmB may be a beneficial target,as GzmB inhibition may reduce direct ECM cleavage (fibronectin),(A)(B)(C)Fig.5GzmB-mediated decorin cleavagerenders collagenfibrils more susceptible todegradation by MMP-1.(A)Decorincleavage assay.Recombinant decorin(0.4l g)was treated with GzmB(100n M)ÆInhibitor(I;50l M)for8h,37°C.(B)Dorsal skin sections from control and UV-irradiated mice were stained with decorinantibody.Intensity of staining in the dermis(excluding hair follicles)was measured bydetecting the number of positive pixelsabove a set threshold,normalized to area.Results are expressed as a percentage ofwild-type control(WT-C)(meanÆSEM;*P<0.05;***P<0.001Tukey’s multiplecomparison).Scale bars=60l m.(C)CollagenfibrilsÆdecorin were treatedwith or without GzmB(100n M)ÆCompound20(I,50l M)as indicated.Lossof intact collagen(closed arrowhead)wasassessed by SDS-PAGE electrophoresisfollowed by Coomassie blue staining.Openarrowhead=bovine serum albumin.Resultsare expressed as a percentage of intactcollagen control(meanÆSEM of threeindependent experiments,*P<0.05;***P<0.001Tukey’s multiplecomparison).GzmB degrades ECM after chronic UV irradiation,L.G.Parkinson et al.7ª2014The Authors.Aging Cell published by the Anatomical Society and John Wiley&Sons Ltd.。